Table 3.

Association between co-trimoxazole and mortality stratified by baseline CD4

Stratified by baseline CD4 (cells/mm3)		Deaths (n)/Person time (yrs)	Unadjusted*	Adjusted*†	Deaths (n)/Person time (yrs)	Adjusted*† (WHO stage 1 or 2 only)
<200	No CPT	626/2818	Referent	Referent	130/928	Referent
	CPT	515/4857	0.51 (0.45–0.58)	0.64 (0.56–0.72)	133/1979	0.52 (0.40–0.68)
200–350	No CPT	83/1336	Referent	Referent	14/534	Referent
	CPT	33/992	0.58 (0.38–0.87)	0.62 (0.41–0.94)	12/462	0.92 (0.42–2.0)
>350	No CPT	23/463	Referent	Referent	6/241	Referent
	CPT	10/284	0.77 (0.36–1.6)	0.80 (0.38–1.7)	6/129	1.7 (0.53–5.2)
p-value for effect modification			0.5	0.8		0.08

^*Controlling for clinic level effects using frailty random effects

^†Adjusted for age, sex, WHO HIV clinical stage, history of tuberculosis, and time updated HIV RNA suppression

CPT, co-trimoxazole preventive therapy